S651
Clinical – Head & neck
ESTRO 2026
treatment delays (overall treatment time ≥ 47 days) occurred in three patients - one due to a competing cancer, another due to brain infarction and one refused treatment. Conclusion: In this group treated according to national guidelines, compliance to cisplatin was overall good across different tumour locations, tumour stage, sex, age and co-morbidities and performance status, without compromising the radiotherapy treatment and overall treatment time. It calls for a less selective approach to concomitant weekly cisplatin.Table 1
Keywords: Cisplatin, curative radiotherapy, compliance
Digital Poster 4161
Figure 1
Long-term outcomes and patterns of failure in non-metastatic olfactory neuroblastoma treated with surgery and adjuvant radiotherapy Sofia Paola Bianchi 1 , Marinella Molteni 1 , Stefania Gottardo 1 , Alberto Daniele Arosio 2 , Gianluca Dalfino 2 , Giorgio Sileo 2 , Alessia Lambertoni 2 , Luca Volpi 2 , Marianna Montesano 1 , Redona Tafili 1 , Federica Piccolo 1 , Daniela Patrizia Doino 1 , Paola Stucchi 3 , Fabio Tanzi 3 , Maurizio Bigniami 2,4 , Italo Dell'Oca 1 1 Division of Radiotherapy, ASST SETTELAGHI Ospedale di Circolo, Varese, Italy. 2 Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences,, University of Insubria, Varese, Italy. 3 Division of Medical Physicist, ASST SETTELAGHI Ospedale di Circolo, Varese, Italy. 4 Head and Neck Surgery & Forensic Dissection Research center (HNS&FDRc), Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
Made with FlippingBook - Share PDF online